Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
| Autor: | Eiseki Usami, Hitomi Teramachi, Michio Kimura, Tomoaki Yoshimura |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Colorectal cancer Leucovorin Antibodies Monoclonal Humanized Irinotecan Ramucirumab 03 medical and health sciences Folinic acid chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Aged Tipiracil Aged 80 and over business.industry General Medicine Middle Aged medicine.disease Survival Rate chemistry Fluorouracil 030220 oncology & carcinogenesis FOLFIRI Female Colorectal Neoplasms business medicine.drug |
| Zdroj: | Anticancer Research. 40:1605-1611 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | BACKGROUND/AIM The aim of this study was to clarify the risk benefits of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as third-line and later-line treatment for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS We compared the overall survival (OS), adverse events (AEs), and cost of F-RAM to those of trifluridine/tipiracil combination tablet (TAS-102). RESULTS There was no significant difference in the median OS [6.1 (range=1.2-16.3) months vs. 6.1 (range=1.2-22.3) months; log-rank test, p=0.272] and treatment duration [4.0 (range=1.2-9.6) months vs. 3.5 (range=0.2-12.3) months, p=0.888] between the F-RAM (n=13) and the TAS-102 (n=36) groups. However, AEs were more frequent in the F-RAM group, and 1-year administration of F-RAM cost higher ($81,724.8 vs. $18,931.4, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|